KANSER HASTALARINDA VİTAMİN VE ANTİOKSİDAN BENZERİ DESTEK TEDAVİLER ALMASI HASTALIĞI SEYRİNİ OLUMSUZ ETKİLEYEBİLİR

Yazar Deniz Tural Son güncelleme Mar 19, 2024 1.341 0

KANSER HASTALARINDA VİTAMİN VE ANTİOKSİDAN BENZERİ DESTEK TEDAVİLER ALMASI HASTALIĞI SEYRİNİ OLUMSUZ ETKİLEYEBİLİR

Kanser hastaları haklı gerekçelerle merak ettiği en önemli konulardan biri, kemoterapi gibi yıpratıcı bir tedavi alırken bağışıklığı güçlendirici ya da vücut direncini artırıcı ek takviye edici destek vitaminler ya da antioksidan tabletleri kapsül şeklinde alabilir miyim?
Bu soru tüm onkoloji branşlarında ana sorunlardan biridir

Yıllardır, eğer tıbbi olarak almanızı gerektirecek bir düzeyde değilse, kapsül şeklinde; Vitamin B6. Vitamin B12. Vitamin E. Vitamin C. Beta carotene, Folic acid, Selenium, Vitamin D ve benzeri kapsüllerin almanın faydalı olmadığını biliyorduk.

Meme kanserli hastalarda yapıla SWOG çalışması, kaygılarımızı başka bir düzeye taşıdı.
Gereksinimi olmayan, destek şeklinde vitamin ve benzeri ek destek tedaviler alanla meme kanseri hastalarında, hastalığın tekrarı daha fazla gözüküyor.

Vücut direncini en iyi şekilde zihinde tutan, düzenli egzersiz, kas kütlesini korumak, mümkün oldukça doğal beslenmektir.

Zararsız ve masum olduğunu düşündüğümüz kapsül şeklinde vitaminler, antioksidan tabletler, kemoterapi ve diğer onkolojik tedavilerin etkinliğini azaltabilir. Bu durumda, yan etkilerine katlanmak zorunda olduğumuz standart tedavilerin başarısız olmasına neden olabilir.

Sonuç: Kanser tedavisi esnasında doktorunuza danışarak, ek gıda almayın. Hem sağlığınızı hem de ekonomik olarak bütçenize zararlıdır. Tüm yan etkilerine katlandığınız tedavinin etkinliğini azaltabilir.

KAYNAK:

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

Christine B. Ambrosone, PhD¹; Gary R. Zirpoli, PhD²; Alan D. Hutson, PhD¹; William E. McCann¹; Susan E. McCann, PhD, RD¹; William E. Barlow, PhD³; …Show More

G.T.B. and K.S.A. are joint senior authors.

Abstract

Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast cancer outcomes.

METHODS

Patients with breast cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at registration and during treatment (n =1,134). Cox proportional hazards regression adjusting for clinical and lifestyle variables was used. Recurrence and survival were indexed at 6 months after enrollment using a landmark approach.

RESULTS

There were indications that use of any antioxidant supplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was associated with an increased hazard of recurrence (adjusted hazard ratio [adjHR], 1.41; 95% CI, 0.98 to 2.04; P = .06) and, to a lesser extent, death (adjHR, 1.40; 95% CI, 0.90 to 2.18; P = .14). Relationships with individual antioxidants were weaker perhaps because of small numbers. For nonantioxidants, vitamin B12 use both before and during chemotherapy was significantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01). Use of iron during chemotherapy was significantly associated with recurrence (adjHR, 1.79; 95% CI, 1.20 to 2.67; P < .01) as was use both before and during treatment (adjHR, 1.91; 95% CI, 0.98 to 3.70; P = .06). Results were similar for overall survival. Multivitamin use was not associated with survival outcomes.

CONCLUSION

Associations between survival outcomes and use of antioxidant and other dietary supplements both before and during chemotherapy are consistent with recommendations for caution among patients when considering the use of supplements, other than a multivitamin, during chemotherapy.